NC 525
Alternative Names: LAIR-1 mAb - NextCure; NC-525Latest Information Update: 12 May 2025
At a glance
- Originator NextCure
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cell death stimulants; Leukocyte-associated immunoglobulin-like receptor 1 antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
Most Recent Events
- 24 Apr 2025 NextCure terminates a phase I trial in Myelodysplastic syndromes, Chronic myelomonocytic leukaemia and Acute myeloid leukaemia in USA as a result of program reprioritization and due to the limited clinical activity observed
- 15 Nov 2023 Pharmacodynamics data from preclinical trial in Acute myeloid leukemia released by NextCure
- 28 Feb 2023 Phase-I clinical trials in Chronic myelomonocytic leukaemia (Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT05787496)